Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email or call 312-355-5112.

ACT16106: Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer

Sponsor: Sanofi
Principal Investigator: Oana Danciu, MD

Translate »